Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Silodosin

Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.

Trial Locations (1)

Unknown

Seoul national university hospital, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Chonnam National University Hospital

OTHER

collaborator

Kangdong Sacred Heart Hospital

OTHER

collaborator

Yeungnam University Hospital

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Chonbuk National University Hospital

OTHER

collaborator

Asan Medical Center

OTHER

lead

JW Pharmaceutical

INDUSTRY